Clinical Trial

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-19
Trial Details
NCT Number NCT04520139
Lead Sponsor University of California, Irvine
Collaborators: Jarrow Formulas Inc
Conditions Ovarian Cancer, Cognitive Impairment
Enrollment 102 participants
Start Date 2026-05-21
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-17